TRISCEND II randomized trial data presented at ACC show lower mortality with EVOQUE system, when accounting for patient crossover
/Edwards%20Lifesciences%20Corp%20Irvine%2C%20Ca%20campus-by%20Steve%20Cukrov%20via%20Shutterstock.jpg)
Edwards Lifesciences will release its first-quarter earnings soon, and analysts anticipate a double-digit bottom-line growth.
/Edwards%20Lifesciences%20Corp%20logo%20on%20phone-%20by%20IgorGolovniov%20via%20Shutterstock.jpg)
Edwards Lifesciences has outperformed the S&P 500 recently, and analysts remain moderately optimistic about the stock’s prospects.
At the close of Heart Month, Edwards Lifesciences (NYSE: EW) underscored its leadership in structural heart innovation, advancing care through deep expertise and strong partnerships so people with structural...
Edwards Lifesciences Corporation (NYSE: EW) today announced its chief financial officer, Scott Ullem, is scheduled to present at two upcoming conferences: Tuesday, March 10, 2026...
Edwards Lifesciences Corporation (NYSE: EW) today announced it will participate in Citi’s Unplugged Medtech and Life Sciences Access Day on February 26, 2026. Scott Ullem, chief financial...
With after-tax profits surging by close to 50% year-over-year, AstraZeneca emerges as a potential winner among healthcare names reporting earnings this month.
Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter and full-year ended Dec. 31, 2025. Highlights and Outlook ...
While Edwards Lifesciences has underperformed the S&P 500 over the past 52 weeks, Wall Street analysts maintain a moderately optimistic outlook about the stock’s prospects.
Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended December 31, 2025 after the market closes on Tuesday, February 10, and will host a conference call at 5:00...